Depo-Provera Shortage Update: What Patients Need to Know in 2026

If you've been searching for information about a Depo-Provera shortage, you're not alone. Thousands of patients across the United States struggle every year to locate this widely used birth control injection. In 2026, the situation is nuanced—here's exactly what's happening and what you need to know.

Is Depo-Provera in an Official FDA Shortage in 2026?

No. As of 2026, Depo-Provera (medroxyprogesterone acetate injectable suspension, 150 mg/mL) is not listed on the FDA's Drug Shortage Database. This means manufacturers have not formally reported supply disruptions that would trigger an official shortage designation.

However, the absence of an official shortage doesn't mean every patient can easily access their injection. A medication can be technically "available" in national supply while being consistently out of stock at specific pharmacies or in specific regions. This is the reality many Depo-Provera patients face.

What Is Actually Happening with Depo-Provera Availability?

The access challenges with Depo-Provera are driven by structural factors rather than a manufacturing crisis:

Clinic-based administration: Unlike oral pills, Depo-Provera requires in-person injection by a healthcare professional. Supply is split between clinics, OB/GYN offices, and retail pharmacies—making it harder to track and access.

Demand-driven pharmacy ordering: Chain pharmacies often stock medications based on local prescription volume. Low-traffic areas may not carry the injection at all.

Shifting demand post-meningioma warning: Following the FDA's December 2025 label update linking Depo-Provera to meningioma brain tumors, some patients are switching to alternatives, which may affect local stock patterns.

Generic vs. brand stocking: Some pharmacies only stock generic medroxyprogesterone acetate injection, not the Depo-Provera brand specifically. These are therapeutically identical—always ask for the generic if the brand isn't available.

The December 2025 FDA Meningioma Warning: What It Means for You

The biggest news surrounding Depo-Provera in 2026 isn't a supply shortage—it's the FDA's approval of a new safety warning about meningiomas. In December 2025, the FDA required Pfizer to add language to the Depo-Provera label stating:

"Cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use. Monitor patients on Depo-Provera CI for signs and symptoms of meningioma. Discontinue Depo-Provera CI if a meningioma is diagnosed."

A 2024 French study found that women who used Depo-Provera for more than one year were approximately 5.5 times more likely to develop a meningioma requiring surgery. Canada and the EU had already required this warning since 2022–2024. As of May 2026, over 3,490 lawsuits are pending against Pfizer in federal court related to meningioma diagnoses.

This warning does not mean Depo-Provera is banned or being pulled from the market. It remains FDA-approved. But it does mean every current and potential user should have an informed conversation with their healthcare provider about their personal risk level and whether an alternative is appropriate.

What Should Patients Do Right Now?

Talk to your provider about the meningioma warning. Discuss your personal risk factors, duration of use, and whether switching to an alternative is recommended.

Report any new headaches, vision changes, or neurological symptoms. These can be early signs of meningioma and should prompt immediate medical evaluation.

If you're continuing on Depo-Provera: Plan ahead for your next injection. Use medfinder to locate pharmacies or clinics near you that have the injection in stock.

Ask about generic availability. Generic medroxyprogesterone acetate injection 150 mg/mL is therapeutically equivalent to brand-name Depo-Provera and may be easier to find.

Looking Ahead: Will Depo-Provera Face Future Supply Issues?

The ongoing litigation and growing awareness of the meningioma risk may shift prescribing patterns over the next 1–2 years. If providers increasingly recommend alternatives, demand for Depo-Provera may decrease, which could actually ease availability for patients who choose to remain on it. No supply disruption is anticipated at the manufacturing level in 2026.

For information on alternatives, see our guide: Alternatives to Depo-Provera If You Can't Fill Your Prescription.